| Description | PC945 (Opelconazole) is a potent broad-spectrum antifungal compound with inhibitory effect on fumonisinol 14α-demethylase (CYP51A/CYP51B), which can be used in the study of fungal infections of the lungs. |
| In vitro | PC945是一种吸入途径给药的三唑类抗真菌化合物[1]。在针对可用唑类化合物治疗的NCPF2010菌株的抗真菌活性测定中，PC945展现出较强效力，其最小抑菌浓度（MIC）值为0.063 µg/mL[1]。 |
| In vivo | 化合物PC945 (0.56-14 μg/只小鼠；鼻腔内给药；每日一次，连续7天) 大幅抑制了滚动行为的发生[2]。 |
| Target activity | CYP51A:0.23 μM, CYP51B:0.22 μM |
| Synonyms | Opelconazole |
| molecular weight | 682.73 |
| Molecular formula | C38H37F3N6O3 |
| CAS | 1931946-73-4 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 80 mg/mL (117.18 mM), Sonication is recommended. |
| References | 1. Colley T, et al. Antifungal synergy of a topical triazole, PC945, with a systemic triazole against respiratory Aspergillus fumigatus infection. Sci Rep. 2019 Jul 1;9(1):9482. 2. Colley T, et al. In Vitro and In Vivo Antifungal Profile of a Novel and Long-Acting Inhaled Azole, PC945, on Aspergillus fumigatus Infection. Antimicrob Agents Chemother. 2017 Apr 24;61(5). pii: e02280-16. |